Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
135.8 USD | -1.93% | +0.12% | +7.39% |
Jun. 05 | European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading | MT |
Jun. 03 | Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.39% | 7.94B | |
+18.97% | 125B | |
+14.55% | 108B | |
-4.58% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-12.88% | 16.5B | |
+2.91% | 13.39B | |
+28.17% | 11.1B |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH